Aguracingene cadoparvovec

DB16813InvestigationalGene Therapies

Aguracingene cadoparvovec: Overview.

Code names
AAV-CNGA3

Resolves to

Compound
UNIIUF5FV8MLZ2CAS2417550-70-8

What you can answer from here — as of October 30, 2025

2Clinical trialsPhase, status and sponsor resolved per trial
Sign in

Which companies are running trials of Aguracingene cadoparvovec, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In